What Bans Actually Do
Rhode Island's lawmakers reversed their kratom ban because it "wasn't effective and hadn't stopped products from being sold illegally." Alabama has had kratom as a Schedule I felony since 2016 and still needed a statewide enforcement wave in 2026. Here is what the evidence shows bans actually produce.
TL;DR: What the Evidence Shows
- Bans do not eliminate demand. Alabama banned kratom as a Schedule I felony in 2016. A decade later, the state Attorney General had to issue a statewide cease-and-desist because kratom was still being sold in stores across the state, relabeled under product names that concealed its presence.
- Prohibition removes quality controls without removing products. Under a ban, products continue to circulate but can no longer be labeled, tested, or regulated. Consumers cannot know what they are buying. This makes the contamination problem worse, not better.
- Dependent users do not simply stop needing access. Someone managing chronic pain or opioid recovery with kratom does not stop needing pain management because kratom became illegal. They find alternatives, often more dangerous ones. The 2018 HHS finding warned of exactly this outcome.
- Enforcement falls on the retail layer, not the production layer. Manufacturers adapt quickly. Small retailers absorb the risk. Consumers turn to unregulated sources. The people hurt most by prohibition are rarely the people producing the problem.
- A documented alternative exists and is working. More than 20 states regulate kratom instead of banning it. Rhode Island tried prohibition, documented its failure, and chose regulation instead. The outcomes are not theoretical.
Prohibition Does Not Eliminate Demand
The assumption underlying every ban is that making something illegal causes people to stop using it. The evidence from states that have banned kratom does not support that assumption.
Alabama: A Decade of Schedule I, Still On the Shelves
Alabama was the first state in the country to classify kratom as a Schedule I controlled substance, in 2016. Knowing possession of any quantity is a Class C felony. Manufacture, delivery, or sale is a Class B felony. Enhanced penalties apply for sales near schools. This is not a regulatory tap on the wrist. It is criminal prohibition with real felony consequences.
"We've discovered through independent lab testing that kratom has made its way back into Alabama through improperly labeled products."
Alabama Attorney General Steve Marshall, March 25, 2026
Ten years after Alabama made kratom a Schedule I felony, the state Attorney General had to issue a statewide cease-and-desist order because kratom was still being actively sold in stores across the state. The products had been relabeled under consumer-product names, including "Boujee Bliss," "Better Weather," and "Happy Hour," marketed for pain relief and relaxation, with no disclosure of kratom content. Independent laboratory testing confirmed the presence of mitragynine in these products.
This is not evidence that enforcement failed. It is evidence that prohibition, even vigorous prohibition with felony consequences, does not eliminate a market where real consumer demand exists. It relocates the market and conceals it. Ten years of Schedule I classification did not eliminate kratom sales in Alabama. It produced kratom sales under fake product names with undisclosed ingredients.
The Alabama Enforcement Record
2016: Alabama classifies kratom as Schedule I under Ala. Code § 20-2-23. Possession becomes a Class C felony; sale becomes a Class B felony.
March 25, 2026: Alabama AG Steve Marshall issues a statewide cease-and-desist order following independent lab testing that confirmed kratom in products sold under unrelated brand names on store shelves across the state.
The AG coordinated enforcement efforts with local district attorneys and law enforcement agencies statewide. The cease-and-desist was not a routine action. It was a documented acknowledgment that a decade of felony-level prohibition had not cleared the market.
Source: Alabama Attorney General's Office press release, March 25, 2026
Rhode Island: The State That Documented Prohibition's Failure
Rhode Island banned kratom in 2017. In July 2025, Rhode Island became the first state in the country to reverse a kratom ban, replacing prohibition with a regulated framework effective April 1, 2026. Rhode Island legislators said directly that the ban "wasn't effective and hadn't stopped products from being sold illegally."
"The ban wasn't effective and hadn't stopped products from being sold illegally."
Rhode Island lawmakers, on the reason for reversing the state's kratom ban, 2025
This is not an advocacy group's characterization of the ban's failure. It is the assessment of the legislators who observed the ban operating for eight years and chose to replace it. Rhode Island issued its first kratom manufacturer license under the new KCPA-style framework in June 2026.
Prohibition Removes Quality Controls Without Removing Products
The documented harms attributed to kratom products are largely harms of an unregulated market. Prohibition does not regulate that market. It simply removes the legal, testable layer from it.
The Alabama case illustrates the specific mechanism. Under prohibition, products containing kratom continued to be sold. But because they were illegal, they could not be labeled accurately, could not carry mandatory lab certifications, and could not disclose their actual contents. Consumers buying "Happy Hour" or "Better Weather" at a gas station had no way to know they were purchasing a Schedule I controlled substance, let alone one of unknown potency and purity.
This is the precise opposite of what a testing-and-labeling framework produces. In states with Kratom Consumer Protection Act frameworks, products must carry certificates of analysis from third-party laboratories, disclose their alkaloid content, and carry age restrictions. A consumer in a KCPA state can know what they are buying. A consumer in a ban state cannot, because the product cannot legally acknowledge what it is.
The Contamination Problem Gets Worse Under Prohibition
The federal record attributes a portion of kratom-related adverse events to contamination with tianeptine, a substance with severe opioid-like dependence properties. Tianeptine contamination is a problem of unregulated production. Under prohibition, the legal, testable market is eliminated. Production does not stop; it moves to sources with no regulatory accountability, no testing requirements, and no labeling standards. The contamination problem that exists under unregulated commerce does not improve when the regulated channel is removed. It gets worse.
A ban does not clean up the products that were causing harm. It removes the only products that were subject to any quality control at all.
What the Alabama Enforcement Action Actually Found
When the Alabama AG's office conducted independent laboratory testing, it found kratom being sold under consumer-product brand names with no ingredient disclosure. The products were not coming from a regulated supply chain with test results. They were unregulated products, circulating in an illegal market, with no accountability for content, potency, or adulterants.
This is what prohibition consistently produces: not an absence of the product, but a version of the product that is less safe, less transparent, and less accountable than the legal version it replaced.
What Unregulated Products Look Like Under Prohibition
Products seized in Alabama's 2026 enforcement action were marketed for "pain relief and relaxation" with no disclosure that they contained a Schedule I controlled substance. The AG's own warning to consumers noted that "product labels for these items may not fully disclose all ingredients, meaning purchasers may unknowingly possess a controlled substance and are at risk of experiencing adverse health events upon ingestion."
That warning is from the state that banned kratom. The risk it describes, that consumers cannot know what they are taking, is a direct consequence of prohibition, not a problem that prohibition solved.
Source: Alabama Attorney General's Office press release and cease-and-desist order, March 25, 2026
Dependent Users Do Not Simply Stop Needing Access
The population using kratom for pain management or opioid recovery does not disappear when kratom becomes illegal. They find alternatives. The federal government's own 2018 assessment warned of exactly this outcome.
In 2018, the Department of Health and Human Services formally recommended against scheduling kratom, warning that doing so would create "a significant risk of immediate adverse public health consequences for potentially millions of users." The letter named intractable pain patients specifically and warned that removing access would push people toward heroin and fentanyl. This was the federal government's own documented concern about the consequences of prohibition.
That concern is not abstract. When kratom becomes unavailable through legal channels, people who were using it to manage chronic pain or maintain sobriety from opioids must make a different choice. The most common alternatives, prescription opioids and illicit opioids, carry significantly higher risks than the product they are replacing. The substitution is not neutral. It has measurable consequences for the people involved.
The Tolerance-Drop Mechanism
One specific, documented mechanism makes this worse for people in opioid recovery. When someone substitutes kratom for opioids over a sustained period, their tolerance to opioids falls. If access to kratom is then removed, and that person returns to opioids, they return with a lower tolerance than they had before. The same dose that was once manageable can now cause an overdose. This is the same well-documented process that makes the period immediately after leaving detox or incarceration so dangerous: tolerance drops during abstinence, and re-exposure at previous doses can be fatal.
A kratom ban does not protect people in recovery. For some of them, it removes the one tool that was functioning as a bridge away from more dangerous substances, and the bridge collapses at the worst possible moment.
The 2018 HHS Warning
The Department of Health and Human Services formally recommended against scheduling kratom and 7-OH in 2018, warning that removing access would create "a significant risk of immediate adverse public health consequences for potentially millions of users," and specifically naming the risk of people being pushed toward heroin and fentanyl as a consequence of scheduling.
This warning was issued by the same federal department now recommending the action it warned against. The current notice does not address this prior finding anywhere in its text.
Enforcement Falls on the Retail Layer
Drug prohibition enforcement does not distribute evenly across the supply chain. It concentrates on the most visible and least mobile layer: retail. Manufacturers and distributors adapt faster than enforcement can follow.
The Alabama case illustrates this directly. After a decade of Schedule I prohibition, kratom remained available in stores across the state. The enforcement response was a cease-and-desist directed at retail businesses, not at manufacturers or the supply chain that produced the relabeled products. The retailers bear the compliance risk; the production layer that supplied them had already adapted to operate under mislabeled product lines.
The K2/Spice synthetic cannabinoid precedent is the most documented version of this pattern. When DEA emergency-scheduled five synthetic cannabinoid compounds in 2011, manufacturers responded by introducing chemically similar but not-yet-scheduled analogs within weeks. DEA had to issue additional emergency scheduling actions in 2013. Congress eventually scheduled 26 compounds at once through the 2012 Synthetic Drug Abuse Prevention Act, because one-at-a-time emergency actions could not keep pace with the substitution rate. The pattern was not theoretical. It played out in real time, documented in Federal Register actions.
Who Enforcement Actually Reaches
Retail level: The most accessible targets. Cease-and-desist orders, shelf inspections, product seizures. Visible, prosecutable, compliance-trackable. This is where enforcement concentrates.
Distributor and manufacturer level: More mobile, better resourced, able to repackage and relabel faster than enforcement can follow. The Alabama relabeled-product problem is a distributor/manufacturer-level adaptation, not a retail-level one. Retailers did not create "Boujee Bliss." Someone supplied it to them.
Consumer level: The people least equipped to adapt. They cannot access the regulated market that no longer exists. They cannot verify what they are buying in the unregulated market that continues. They absorb the risk that prohibition creates without having created the problem prohibition is meant to address.
The Selective Compliance Problem
California's prohibition enforcement provides another illustration. Governor Newsom's office announced in March 2026 that the state had achieved "95% compliance" among regulated businesses, with more than 3,300 products removed and over five million dollars in products seized. This was presented as evidence that prohibition was working.
What the 95% compliance figure measures is compliance among ABC-licensed businesses, primarily liquor stores and bars. Kratom is primarily sold in smoke shops, vape shops, gas stations, and convenience stores, which are generally not ABC-licensed. The compliance figure covers a subset of the retail landscape where kratom was sold. The broader market, the one where most kratom transactions actually occur, was not captured in that compliance measurement.
What Each Approach Actually Produces
The choice is not between a regulated market and no market. It is between a regulated market and an unregulated one. Here is what each approach produces in practice, based on documented state-level experience.
Prohibition States
- Products continue to circulate through unregulated channels
- No labeling requirements, no ingredient disclosure
- No adulterant screening or certificate of analysis
- Consumers cannot verify content or purity
- Enforcement concentrates on retail; manufacturers adapt
- Dependent users lose access to a known product and may substitute more dangerous alternatives
- Relabeling under innocuous names obscures presence of controlled substance
- Criminal exposure for consumers and retailers
KCPA Regulation States
- Products must carry third-party lab certificates of analysis
- Full alkaloid content disclosure required on labels
- Mandatory adulterant screening including tianeptine
- Consumers can verify what they are purchasing
- Retailer licensing creates accountability
- 21+ age restriction limits youth access
- No criminal exposure for compliant consumers
- Regulatory framework can be updated as evidence develops
The State That Tried Both
Rhode Island banned kratom in 2017. After eight years, the state's own lawmakers described the ban as ineffective and noted it had not stopped illegal sales. In July 2025, Rhode Island signed the Kratom Act, replacing prohibition with a KCPA-style regulated framework effective April 1, 2026. The framework includes retailer licensing, a 21-plus age requirement, mandatory product testing, and a continued ban on synthetic 7-OH.
Rhode Island issued its first kratom manufacturer license under the new framework in June 2026. Rhode Island is the only state to have tried prohibition, documented its failure on the record, and reversed course to a regulated framework. It is the clearest available test of what the two approaches produce.
The State With the Longest Ban
Alabama classified kratom as Schedule I in 2016, the first state to do so. A decade later, in March 2026, the state AG issued a statewide cease-and-desist order because kratom was actively being sold in stores under mislabeled product names. The enforcement action was described as a response to independent laboratory testing that confirmed kratom's presence in products consumers had no way to identify as containing a controlled substance.
Ten years of felony-level prohibition produced not an absence of kratom in Alabama, but a version of the kratom market that is less safe, less transparent, and less accountable than any regulated alternative would be.
The Alternative Is Already Working
More than 20 states regulate kratom rather than banning it. The regulatory framework they use is documented, operational, and directly addresses the problems that prohibition fails to solve.
The Kratom Consumer Protection Act
The KCPA, now enacted in more than 20 states including Utah, Georgia, Arizona, Nevada, Oregon, Colorado, Oklahoma, Maryland, Kentucky, South Carolina, West Virginia, and Missouri, establishes:
- Mandatory third-party laboratory testing with adulterant screening for every product batch
- Certificate of analysis requirements, publicly verifiable
- Full alkaloid content disclosure on product labels
- 21-plus age restriction on all kratom sales
- Retailer licensing and registration
- An explicit ban on adulterated or synthetically enhanced products, including those containing tianeptine
This framework addresses the specific, documented harms the scheduling action cites: contamination, inconsistent labeling, and youth access. It does so through accountability mechanisms that prohibition, by definition, cannot provide for an illegal product.
The choice North Dakota faces at its September 2 special session is not between a safe market and an unsafe one. It is between a market the state can regulate, monitor, and hold accountable, and a market that will continue to operate regardless of the legal status, but without any of those accountability mechanisms in place.
The Question for Legislators
If the documented goal is reducing harm from kratom products, the question is: which approach produces that outcome?
The evidence from Alabama shows that a decade of felony prohibition did not eliminate kratom from store shelves. It produced mislabeled kratom on store shelves, with no way for consumers to verify what they were buying.
The evidence from Rhode Island shows that prohibition was ineffective enough at eliminating illegal sales that the state's own lawmakers chose to reverse it.
The evidence from 20-plus KCPA states shows that mandatory testing, labeling, and age restrictions are operationally possible and have been implemented without the unintended consequences that prohibition reliably produces.
Legislators who are genuinely concerned about the harms of unregulated kratom products have a better available tool than prohibition. Alabama has shown, over a decade, what the alternative produces.
Prohibition Is Not the Cautious Option
The argument for banning kratom is often framed as the cautious, safe-side choice: we do not fully understand it, so we should restrict access until we do. The evidence from states that have made that choice does not support that framing.
Prohibition removes quality controls from a market that continues to operate. It creates conditions where consumers cannot know what they are purchasing. It pushes dependent users toward more dangerous alternatives. It concentrates enforcement on the visible retail layer while the supply chain adapts. And, as Rhode Island's lawmakers said directly, it does not stop products from being sold illegally.
Regulation, by contrast, creates mandatory testing, mandatory labeling, and mandatory accountability. It does not require believing kratom is risk-free. It requires recognizing that a legal, testable, labeled product is safer for consumers than an illegal, untested, unlabeled one, and that the market exists regardless of which version the state chooses to permit.
Rhode Island tried prohibition and chose regulation instead. Alabama has had prohibition for a decade and is still conducting enforcement sweeps. More than 20 states are regulating kratom successfully right now. The outcomes of both approaches are documented. The question is which documented outcome legislators want to produce.
A Note on Sources
All claims in this article are drawn from primary sources: the Alabama Attorney General's own press release and cease-and-desist order (March 25, 2026); Rhode Island legislative record and reporting on the Kratom Act (July 2025); the 2018 HHS letter to the DEA authored by Assistant Secretary Brett Giroir; state legislative records for KCPA adoptions; and reporting from the Kratom News Today 2026 Midyear Report and Quick.md state-by-state update. No claim rests on advocacy group characterizations alone.
Continue the Investigation
How a Crisis Gets Built
The statistics behind the bans don't hold up against the primary sources. No single-substance deaths. A manufactured escalation. An inflated adverse-event count.
The Patent Race
MSKCC and Columbia hold patents on kratom-derived compounds. Sparian Biosciences and Kures are developing the prescription replacements. The cannabis playbook, documented.
Does 7-OH Meet the Legal Standard?
The specific statutory test the DEA must clear for emergency scheduling, read against its own record. The prior HHS finding it never addresses.
The Evidence Is There. Use It.
Rhode Island reversed its ban. Alabama is still issuing enforcement waves a decade in. More than 20 states regulate instead of banning. The outcomes of both approaches are documented and available.